Patent ID: 6335348
Filing Date: 2002-01-01
Classification: A61K,A61P,C07D

Abstract:
A method for treating a nerve-related vision disorder or treating memory impairment in an animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:A is O, NH, or N-(C1-C4 ailkyl); B and D are independently H, Ar, C5-C7 cycloalkyl substituted C1-C6 straight or branched chain alkyl, C5-C7 cycloalkyl substituted C2-C6 straight or branched chain alkenyl, C5-C7 cycloalkenyl substituted C1-C6 straight or branched chain alkyl, C5-C7 cycloalkenyl substituted C2-C6 straight or branched chain alkenyl, Ar substituted C1-C6 straight or branched chain alkyl, or Ar substituted C2-C6 straight or branched chain alkenyl, wherein one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) independently selected from the group consisting of oxygen, sulfur, SO, and SO2 in chemically reasonable substitution patterns, or B and D are independently the fragment â€ƒwherein Q is hydrogen, C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl; and T is Ar or C5-C7 cycloalkyl substituted at positions 3 and 4 with substituents independently selected from the group consisting of hydrogen, hydroxy, O-(C1-C4 alkyl), O-(C2-C4 alkenyl), and carbonyl; Ar is selected from the group consisting of 1-naphthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms independently selected from oxygen, nitrogen and sulfur, wherein Ar may contain 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxymethyl, nitro, CF3, trifluoromethoxy, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, O-(C1-C4 straight or branched chain alkyl), O-(C2-C4 straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, 1,2-methylenedioxy, carbonyl, and phenyl; L is either hydrogen or U and M is either oxygen or CHâ€”U, provided that if L Is hydrogen, then M is CHâ€”U, or if M is oxygen then L is U; U is hydrogen, O-(C1-C4 straight or branched chain alkyl), O-(C2-C4 straight or branched chain alkenyl), C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C5-C7 cycloalkyl, C5-C7 cycloalkenyl substituted with C1-C4 straight or branched chain alkyl or C2-C4 straight or branchod chain alkenyl, (C1-C4 alkyl or C2-C4 alkenyl)-Ar, or Ar; J is hydrogen, C1 or C2 alkyl, or benzyl; K is C1-C4 straight or branched chain alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a 7 membered heterocyclic ring which may contain an O, S, SO, or SO2 substituted therein; and m is 0-3, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders, of the lacrimal apparatus; disorders of the eyelids; disorders of the conjunctiva; disorders of the cornea; cataract; disorders of the uveal tract; disorders of the retina; disorders of the optic nerve or visual pathways; free radical induced eye disorders and diseases; immunologically-mediated eye disorders and diseases; eye injuries; and symptoms and complications of eye disease, eye disorder, and eye injury.